Home / Market News / $SRPT

$SRPT news and market catalysts

The 3 most recent market catalysts affecting $SRPT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

3 catalysts 1 high impact 0 bullish 1 bearish Biotechnology

Sep 8, 2026 Corporate Catalyst Bearish Impact 75

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Novartis AG announced that its Phase 3 HARBOR study for del-desiran in myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint. This news directly impacted Sarepta Ther…

Jul 27, 2026 Corporate Catalyst Neutral Impact 75

Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram

Sarepta Therapeutics has announced a significant leadership transition with the appointment of Michael Severino as CEO, effective July 28, 2026, replacing the retiring Doug Ingram.…

Jul 27, 2026 Corporate Catalyst Neutral Impact 95

FDA Staff Review Says Data For Co's Duchenne Cell Therapy Does Not Provide Substantial Evidence Of Effectiveness

The FDA staff review, released ahead of an advisory committee meeting, states that the data for the company's Duchenne cell therapy does not provide substantial evidence of effecti…

Join the waitlist for full signal validation →

New to reading filings? What an SEC 8-K is and why it moves prices

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.